Glucotrack Submits IDE for 3-Year Lifespan Implantable Glucose Monitor Study
Glucotrack submitted its Investigational Device Exemption application to the FDA on May 7 to launch a U.S. clinical study of its fully implantable continuous blood glucose monitoring system. The sensor is designed for up to three years of use without external wearables or frequent calibration.
1. IDE Submission Milestone
On May 7, 2026, Glucotrack filed its Investigational Device Exemption application with the U.S. Food and Drug Administration to initiate a clinical study of its fully implantable continuous blood glucose monitoring (CBGM) technology. This filing follows several years of preclinical development and represents a critical step toward clinical evaluation.
2. Device Features and Design
The implantable CBGM system offers up to three years of continuous glucose measurement without an external wearable component and requires minimal calibration. Its discreet, long-term design aims to enhance patient comfort and adherence by eliminating frequent sensor changes and visible devices.
3. Clinical Study and Commercial Outlook
Pending FDA approval, Glucotrack plans to begin patient enrollment and collect clinical data to support future regulatory submissions. Success in U.S. trials could accelerate the company’s entry into the continuous glucose monitoring market, providing a novel long-term solution for people with diabetes.